annual meeting program - American Society of Clinical Oncology

Monday, June 7, 2010
Brd. 45B A randomized, double-blind, placebo-controlled phase II study of the efficacy
and safety of farletuzumab (MORAb-003) in combination with weekly
paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian
cancer. (Abstract #TPS255)
L. Elit, J. A. Konner, D. K. Armstrong, M. Buck, A. Dean, N. J. Finkler, A. Hulstine,
C. Schweizer, M. Phillips, S. Weil
Brd. 45C Randomized phase II trial of pegylated liposomal doxorubicin (PLD) with or
without anti-platelet-derived growth factor receptor-alpha (PDGFR-alpha)
monoclonal antibody IMC-3G3 in platinum-refractory/resistant advanced
ovarian cancer. (Abstract #TPS256)
W. P. McGuire, G. D. Shah, N. Loizos, H. Youssoufian, E. K. Rowinsky, M. E. Gore
Brd. 45D A randomized phase II study of paclitaxel/carboplatin with or without
sorafenib in the first-line treatment of patients with stage III/IV epithelial
ovarian cancer. (Abstract #TPS257)
J. D. Hainsworth, T. M. Numnum, G. G. Rao
Brd. 45E Phase II study of clinical activity of pegaspargase in women with relapsed or
refractory epithelial ovarian, fallopian tube, and/or primary peritoneal cancer.
(Abstract #TPS258)
G. Kim, J. Squires, M. Yu, A. Walker, N. D. Houston, L. Otten, E. C. Kohn
Brd. 45F A phase II trial of oral etoposide and intravenous irinotecan for patients with
platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503).
(Abstract #TPS259)
K. Matsumoto, N. Katsumata, I. Saito, I. Konishi, T. Kamura, Japan Clinical
Oncology Group
Brd. 45G Enrolling a rare patient population: Establishing proof of concept for FP-
1039, an FGF “trap,” in endometrial cancer patients with the S252W FGFR2
mutation. (Abstract #TPS260)
H. N. Keer, T. C. Harding, W. M. Kavanaugh
Brd. 45H A prospective study to evaluate the efficacy of curcumin in the management
of advanced carcinoma cervix. (Abstract #TPS261)
S. K. Jain, N. Singh, D. Sharma, G. K. Rath, P. K. Julka, P. Heera, B. Ayan, S. Sen,
S. Thulkar, S. Duttagupta
Head and Neck Cancer
Brd. 46A A phase II trial of postoperative radiotherapy (RT), cisplatin, and
panitumumab in patients with high-risk, resected locally advanced
squamous cell carcinoma of the head and neck (SCCHN). (Abstract #TPS262)
R. L. Ferris, A. P. Kotsakis, D. E. Heron, S. Kim, U. Duvvuri, G. J. Kubicek, J. R.
Grandis, J. T. Johnson, A. Argiris
Brd. 46B Phase II trial of everolimus with sorafenib for patients with differentiated
thyroid cancer (DTC) who progress on sorafenib alone. (Abstract #TPS263)
M. S. Brose, A. B. Troxel, R. Mamtani
Brd. 46C Phase II randomized trial of radiotherapy (RT), cetuximab (E), and
pemetrexed (Pem) with or without bevacizumab (B) in locally advanced
squamous cell carcinoma of the head and neck (SCCHN). (Abstract #TPS264)
A. P. Kotsakis, D. E. Heron, G. J. Kubicek, R. L. Ferris, S. Kim, M. K. Gibson, U.
Duvvuri, J. R. Grandis, J. T. Johnson, A. Argiris
Brd. 46D Docetaxel, cisplatin (TP), and radiation with or without cetuximab in
advanced larynx carcinoma (DeLOS II trial). (Abstract #TPS265^)
A. Dietz, M. Flentje,R. Hagen, RD Kortmann, G. Hildebrand, F. Hoppe, I.
Schwienhorst, U. Keilholz
Brd. 46E A phase I/II study of erlotinib in combination with chemoradiation in patients
with surgically resected locally advanced squamous head and neck cancer
(HNSCC). (Abstract #TPS266)
F. Arias de la Vega, I. Herruzo, M. de las Heras, A. de la Torre, V. Arrazubi, J.
Contreras, J. Garcia Saenz, J. Romero, J. Serrano, F. A. Calvo, Grupo de
Investigación Clínica en Oncología Radioterápica (GICOR)
327
MONDAY